SHARING BIPOLAR.com

• Overview
• Breastfeeding
• Medication and conception

Overview

• All four guidelines (BAP, CANMAT, NICE, and SIGN) concur that bipolar disorder has significant implications for reproductive health issues, particularly in relation to the teratogenetic risk caused by the medications being taken for the disorder.
• The figures published in the BAP guideline about the ‘risk of major congenital malformations’ differ slightly from those published in the SIGN guideline (BAP: the risk ‘in the general population is surprisingly high at 2% to 4%’; SIGN: ‘The overall risk of major fetal malformation in any pregnancy of approximately 2% is increased two or three-fold in women taking a single anticonvulsant drug’). The CANMAT and NICE guidelines do not give these statistics.
• Most significantly, the BAP guideline details that lithium and valproate can be continued during pregnancy, although preferably in slow-release formulations. The CANMAT guideline also argues that mothers can continue to take lithium as a mood-stabilizer, instead of other anticonvulsants. SIGN concurs with both guidelines in relation to lithium, yet mentions that ‘Valproate should be avoided as a mood stabilizer in pregnancy.’ NICE gives different advice: ‘Do not routinely prescribe for pregnant women: valproate… [or] lithium’, unless the woman experiences severe mania. In this case, ECT and lithium are preferred over valproate.
• SIGN is the only guideline which mentions that: ‘Benzodiazepines should be avoided in the first trimester of pregnancy’.
• BAP and NICE agree that ECT can be ‘safely administered to pregnant women’. SIGN and CANMAT do not mention ECT.

Read the rest of this entry »

Here are a few things we think you should know that may help you understand our aims.

The World Health Organisation has identified bipolar disorder as one of the top causes of lost years of life and health in 15-44 year olds, ranking above war, violence and schizophrenia. This is not to be taken lightly – the effects of Bipolar Disorder are far reaching…
Read the rest of this entry »

Instructions

At this time there is currently no laboratory tests to confirm a diagnosis of Bipolar Disorder. However, there are many tools a clinician can use to see if a patient does indeed have the disorder. Bipolar Disorder is difficult to diagnose because of its vacillating symptoms. In general, there is no consistency to the symptoms of the disorder, which makes it difficult for the clinician to pinpoint. We’ll explain what tools a clinician has and what are their limitations. Read the rest of this entry »

Cardiff University is undertaking Bipolar Disorder research in close collaboration with their colleagues at Birmingham University (led by Dr Lisa Jones). Members of their team are based in both centres.

Over 3000 people have already participated in our Bipolar Disorder Study and it is now the largest such study anywhere in the world. We are, however, still looking for more volunteers to help us with our research – every additional person who helps will bring the possibility of much-needed scientific advances nearer. If you suffer with bipolar disorder and would like to help by participating in our research, please contact them… Read the rest of this entry »